A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Stage II-III, Estrogen Receptor Positive, HER2-negative Breast Cancer (DARE)
The purpose of this research is to find out if detecting cancer-related abnormal DNA molecules in your blood, called circulating tumor DNA, or ctDNA, can predict a subsequent clinical recurrence of the cancer, and if starting a new treatment when we first detect ctDNA in your blood could prevent, or delay, the clinical recurrence of the cancer.
High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Have Stage II or II, HER2-negavie, ER-positive invasive breast cancer
Currently receiving endocrine therapy and have completed at least 6 months, but no more than 7 years
Clinical and pathological high risk for recurrence
18 - 101
Healthy Volunteers Needed
Duration of Participation
Your participation in this study could last up to 7 years.
Knight Cancer Institute Clinical Trials
CRITERIUM Inc. doing business as Academic Breast Cancer Consortium (ABRCC) with support from Pfizer Pharmaceuticals